Cipla
Dr. Mandar is a medical doctor, and a management graduate from the Jamnalal Bajaj Institute of Management Studies, India.
Mandar spent 15 years at McKinsey (2002-2017), the last seven as partner where he co-led the healthcare practice in India and established the Hospitals practice for Asia. He served leading pharmaceutical companies across India and globally across several areas such as core strategy, manufacturing productivity improvement, R&D productivity, portfolio management, M&A and procurement programs.
From 2017 to 2019 Mandar worked part time advising several healthcare companies, providing leadership coaching and designing and teaching a course on problem solving at Ashoka University.
In Aug 2019, Mandar joined global travel-tech company OYO as CEO – SE Asia & Middle East, driving growth, doubling the number of hotels and homes, while transforming the regions contribution margin to a net positive territory. He led the business through the COVID crisis, improving EBIDTA loss to a negligible level while manging massive business disruptions.
Since March 2021 Mandar is the CEO - OYO Vacation Homes (OVH), Europe, a strategically important core market for the company. OVH is Europe's second largest vacation homes company. Mandar leads three acquired brands, DanCenter, Belvilla and Traum FW, each with a multi decade legacy. He has turbo charged their growth and profitability by migrating them into a tech forward environment while retaining the uniqueness of each businesses bult over the last several decades.
Mandar grew up in Mumbai, but now lives in Gurgaon with his wife and 3-year-old son. He enjoys spending time with his friends, watching movies, and trying out his hand at new pursuits, especially outdoors.
This person is not in the org chart
Cipla
18 followers
Cipla is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.